Aus Bio Ltd. is a public but unlisted, Melbourne based biotechnology research and development company (R&D). Principal objectives are:
Results of the Annual General Meeting held on Thursday, 18th November 2021.Read More
The Annual General Meeting will be held as a Virtual Meeting, on Thursday, 18th November 2021 at 11:00am.Read More
Instructions to log into the 2021 AGM Virtual Meeting.Read More
Link Market Services Ltd has been engaged to provide Virtual Meeting Services to Aus Bio Limited.Read More
Full signed financial statements (financial year 2021).Read More
On behalf of your Board we are pleased to present the 2021 Review of Operations and Corporate Governance Statement.Read More
Melbourne, Australia; 5 March 2020.
A newly formed biopharmaceutical company AusVir Therapeutics Pty Ltd, focused on the development and commercialization of novel medicines targeting viral infection, today announced that it has raised AUD$23 million in a Series A financing led by Morningside Venture Investments.
“New Drugs are Coming to Fight Nasty Flu Seasons”Read More
Aus Bio’s MD2009 project has resulted in the pre-clinical development of a number of antiviral drug candidates which have a different mode of action to the currently used neuraminidase inhibitors.Read More
Aus Bio’s Respiratory Project – MD990 – has resulted from the identification of several specific carbohydrates, which have been shown to influence and enhance recovery of injured human respiratory cells.Read More